With the advent of cutting-edge technologies in the pharmaceutical safety testing landscape, the FDA has released draft guidance aimed at helping drug developers validate New Approach Methodologies (NAMs). This move signals a formal shift away from traditional animal testing as the default regulatory standard, favouring human-centric data to accelerate the delivery of safe, effective therapies to market.
A shift toward human-centric data
For decades, animal testing has been a key part of preclinical safety testing, providing important toxicology and pharmacology data believed to best reflect human clinical trials. However, the Center for Drug Evaluation and Research is now prioritising NAMs – technologies such as organ-on-chips, 3D organoids and AI-driven in silico modelling – as more reliable predictors of human response. The guidance outlines how companies can demonstrate the scientific validity of these tools to gain regulatory confidence.
Dr Marty Makary, Commissioner, FDA, emphasises the necessity of this transition, stating: “Technological advances are allowing us to move beyond animal testing in drug development, which has a poor track record of predicting safety and efficacy in humans.”
The four pillars of validation
The FDA has incorporated four definitive pillars by which pharma companies can qualify and safely integrate NAMs into their applications to ensure these modern tools meet regulatory standards:
- Context of use: Clearly defining how and where the tool will be used in the regulatory process.
- Human biological relevance: Demonstrating how the model accurately assesses human toxicity
- Technical characterisation: Establishing the method is reliable, robust and consistent.
- Fit-for-purpose: Ensuring the data directly aids in regulatory decision-making and drug approval.
Implications for the pharma industry
While the guidance provides a general roadmap, it does not mandate specific technologies. Instead, the FDA encourages developers to meet with its specialised medical teams early in the preclinical stage of testing to ensure new testing methods meet the specific requirements for the disease they are treating. This collaborative approach aims to replace the “animal-first” paradigm with models that better replicate complex human conditions.
Robert F. Kennedy Jr., Secretary, Health and Human Services, emphasised the broader impact of the guidance on future innovation, noting: “Clear validation expectations will help modern tools earn regulatory confidence and speed safer, more effective therapies to patients.”
